Share this article
Share this article
NEW YORK, May 26, 2021 /PRNewswire/ The eyewear market is set to grow by USD 57.69 billion, progressing at a CAGR of almost 8% during 2020-2024. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.
Technavio has announced its latest market research report titled Eyewear Market by Product and Geography - Forecast and Analysis 2020-2024
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Bausch Health Companies Inc, Carl Zeiss AG, De Rigo Vision Spa, EssilorLuxottica, Fielmann AG, Hoya Corp, Kering SA, Marcolin Spa, Rodenstock GmbH, and Safilo Group Spa are some of the major market participants. The increasing prevalence of vision disorder will offer immense growth opportunities. To leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments while mai
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
News provided by
Share this article
Share this article
LAVAL, Quebec, May 27, 2021 /PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company ) today announced it will reduce debt by $100 million through the redemption of outstanding senior notes, using cash generated from operations.
Bausch Health will redeem $100 million aggregate principal amount of its outstanding 6.125% Senior Notes due 2025, CUSIP Nos. 91831A AC5, C96729 AC9 (the Notes ) on June 30, 2021. With the redemption announced today, the Company will have redeemed a total of $500 million aggregate principal amount of debt in 2021 using cash generated from operations.
Data Bridge Market Research has published new report on Plastic Surgery Devices Market by Type (Instruments, Consumables, Implants), End User (Clinic, Medical
Pfizer, Inc. (NYSE: PFE) and
Myovant Sciences (NYSE: MYOV) announced FDA approval for once-daily Myfembree, relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg, for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.
The companies said they will jointly commercialize Myfembree in the U.S. Myfembree is expected to be available in June.
Pfizer shares edged down 0.15% to $38.86 in after-hours trading and Myovant receded 0.34% to $23.60.
Zosano Announces Publication Of Positive Results From Long-Term Use Of Migraine Drug
Zosano Pharma Corporation (NASDAQ: ZSAN) announced that an article titled, Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine was published in the Journal of Headache and Pain
Data Bridge Market Research Adds “Europe Primary Angle-Closure Glaucoma Market – Industry Trends and Forecast to 2028” new report to its research database. The report spread No of pages : 350 No of Figures: 60 No of Tables: 220 in it.This comprehensive Europe Primary Angle-Closure Glaucoma industry research report i.